ASTS February 27th Options Begin Trading

The piece analyzes option strategies on AST SpaceMobile (ASTS), where the $88 put is bidding $10.95 (implying a net purchase basis of $77.05 versus the current stock price of $88.72) and the $92 call bids $11.40 for a covered-call trade if purchasing stock today. The put is out‑of‑the‑money by ~1% with a 60% chance to expire worthless and would produce a 12.44% return (90.84% annualized) on cash committed; the call is ~4% out‑of‑the‑money with a 44% chance to expire worthless and would add a 12.85% yield boost (93.80% annualized) or 16.55% total if called at the Feb. 27 expiration. Implied volatility is ~104% on the put and 103% on the call, versus a trailing-12-month volatility of 99%; Stock Options Channel will track the changing odds and contract histories on its site.

Analysis

Market structure: The immediate beneficiaries are option premium sellers and income-oriented equity holders willing to be assigned (cash‑secured put sellers at $88 or covered‑call writers at $92). Elevated implied vol (103–104% vs. 99% realized) signals concentrated binary risk — likely upcoming corporate/regulatory catalysts — which increases bid for short‑dated protection and compresses liquidity for aggressive longs. Cross‑asset impact is limited but cue higher funding needs for ASTS (equity dilution risk) and transient correlation increases with small‑cap tech/space names and volatility-sensitive ETFs (e.g., ARKK components).

Risk assessment: Tail risks include a launch/regulatory failure or urgent dilutive capital raise that could drop shares >30% (low probability but high impact). Timing: immediate (days) — option decay dominates to Feb 27 expiry; short term (weeks) — IV reprice around announcements; long term (quarters) — commercial traction and balance‑sheet events dictate value. Hidden dependencies: borrow costs, margin on assignment, and dealer positioning can flip skew quickly; IV collapse after a benign news event would punish long‑vol strategies. Key catalysts: FCC/partner filings, launch manifest updates, and any equity capital raise within 30–90 days.

Trade implications: Preferred tactical plays favor selling defined premium: (1) cash‑secured short $88 Feb27 put to target $77.05 basis (60% OTM survival) sized 1–3% NAV; (2) buy up to 2–4% NAV stock and sell $92 Feb27 covered calls to harvest ~16.6% to assignment; (3) for defined risk, sell a Feb27 iron condor (sell 88P/92C, buy 82P/98C) to cap tail exposure while collecting elevated premium. If holding stock full time, buy Mar $60 put (or $66) as a tail hedge.

Contrarian angle: The market is overpaying for binary downside protection in short tails but not for structured sellers who cap risk; implied vol roughly matches realized — so naked long‑vol is expensive on expectation. Historical parallels: small‑cap, event‑driven space/biotech names show that selling short‑dated defined premium with strict assignment rules outperforms outright directional bets. Unintended risk: assignment gaps and post‑assignment dilution can convert an income trade into a large loss — enforce rigid size and stop thresholds.

Key Decisions for Investors

• Establish a cash‑secured short put: sell ASTS Feb27 $88 put size 1–3% NAV (target effective purchase $77.05). Set max loss rule: close or hedge if ASTS < $66 (20% additional gap) or if implied vol rises >20 pts.
• Buy ASTS up to 2–4% NAV and sell Feb27 $92 covered calls (receive $11.40). If assigned, realize ~16.55% gross return; if not, roll monthly and harvest income; cut equity if shares fall >15% from entry.
• Execute a defined‑risk income spread: sell Feb27 $88 put and $92 call while buying protective wings (buy $82 put, buy $98 call) sized to limit one‑way loss to <5% NAV — collect elevated net premium given IV ~103%.
• If holding material long exposure (>4% NAV), buy Mar $60 (or $66) puts as a tail hedge (~protects against >25–35% drop) and reduce exposure before any announced capital‑raise or launch update within 30–90 days.